发明名称 |
Parvovirus modificado que tiene una eficacia antitumoral mejorada |
摘要 |
Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumour potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substituion at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy. |
申请公布号 |
ES2603407(T3) |
申请公布日期 |
2017.02.27 |
申请号 |
ES20110733567T |
申请日期 |
2011.06.17 |
申请人 |
Deutsches Krebsforschungszentrum |
发明人 |
SALOME, Nathalie;DINSART, Christiane;WEISS, Nadine;ROMMELAERE, Jean |
分类号 |
C12N7/00;A61K35/768;C07K14/005;C07K16/08;C12N15/86 |
主分类号 |
C12N7/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|